Karyopharm to Present at SVB Securities Global Biopharma Conference

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) announced participation in the virtual SVB Securities Global Biopharma Conference on February 16, 2023, at 11:20 a.m. ET.

Rhea-AI Summary

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) announced participation in the virtual SVB Securities Global Biopharma Conference on February 16, 2023, at 11:20 a.m. ET. The senior management team will engage in a fireside chat, with a live webcast available for replay on the company's website for 90 days post-event. Karyopharm specializes in novel cancer therapies and is known for its lead compound, XPOVIO® (selinexor), which addresses nuclear export dysregulation in oncogenesis. The company also has a diverse pipeline targeting high unmet cancer needs in multiple myeloma, endometrial cancer, and more. For further details, visit www.karyopharm.com.

Argus Session date unavailable

-0.91% session move Open Argus

Details

News Market Reaction – KPTI

The recorded move for KPTI in the trading session of this news was -0.91%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEWTON, Mass., Feb. 9, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate at the virtual SVB Securities Global Biopharma Conference in a fireside chat on Thursday, February 16 at 11:20 a.m. ET.

A live webcast of the fireside chat, along with accompanying slides, can be accessed under "Events & Presentations" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations, and will be available for replay for 90 days following the event.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company pioneering novel cancer therapies. Since its founding, Karyopharm has been an industry leader in oral Selective Inhibitor of Nuclear Export (SINE) compound technology, which was developed to address a fundamental mechanism of oncogenesis: nuclear export dysregulation. Karyopharm's lead SINE compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications and has received regulatory approvals in various indications in a growing number of ex-U.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO®) and China. Karyopharm has a focused pipeline targeting multiple high unmet need cancer indications, including in multiple myeloma, endometrial cancer, myelodysplastic neoplasms and myelofibrosis. For more information about our people, science and pipeline, please visit www.karyopharm.com, and follow us on Twitter at @Karyopharm and LinkedIn.

XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm Therapeutics Inc. Any other trademarks referred to in this release are the property of their respective owners.

View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-to-present-at-svb-securities-global-biopharma-conference-301742276.html

SOURCE Karyopharm Therapeutics Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What date and time is Karyopharm presenting at the SVB Securities Global Biopharma Conference?

Karyopharm is presenting on February 16, 2023, at 11:20 a.m. ET.

How can I access the Karyopharm presentation from the SVB Conference?

The presentation can be accessed via a live webcast on Karyopharm's website under 'Events & Presentations'.

What is Karyopharm's lead product?

Karyopharm's lead product is XPOVIO® (selinexor), an oral exportin 1 (XPO1) inhibitor.

Which cancer types does Karyopharm's pipeline target?

Karyopharm's pipeline targets multiple myeloma, endometrial cancer, myelodysplastic neoplasms, and myelofibrosis.